BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL.
Saved in:
| Title: | BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL. |
|---|---|
| Authors: | Borchmann, P., Moccia, A. A., Greil, R., Schneider, G., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J. M., Fosså, A., Viardot, A., Hertenstein, B., Martin, S., Giri, P., et al |
| Source: | Hematological oncology Jun2023 Supplement S2; Vol. 41. |
| Journal Info: | Publisher: Wiley-Blackwell ISSN: 0278-0232 |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1099-1069 |
|---|---|
| DOI: | 10.1002/hon.3196_LBA5 |
